ABBV — AbbVie Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1551152 ·
Last close
$264.34
Market Cap
$467.12B
52W High
$269.39
52W Low
$189.40
ADV30
4,229,130
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 16,990,000,000 12,699,000,000 6,723,000,000 3,613,000,000 135,115,000,000 6,569,000,000 141,003,000,000
Mar 2026 — — — — — — —
Dec 2025 16,618,000,000 12,066,000,000 5,809,000,000 1,816,000,000 133,960,000,000 5,229,000,000 137,188,000,000
Sep 2025 15,776,000,000 10,472,000,000 4,584,000,000 186,000,000 133,898,000,000 5,629,000,000 136,497,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$19,507,000,000
Investing CF
$-6,498,000,000
Financing CF
$-12,891,000,000
CapEx
$-1,297,000,000
Dividends Paid
$-11,978,000,000
Buybacks
$-1,505,000,000
EPS Diluted TTM
$3.54
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-17,333,000,000
Inventory
$5,127,000,000
Receivables
$13,824,000,000
ST Investments
$28,000,000
EBIT TTM
$11,615,000,000
Pretax Income TTM
$8,699,000,000
Interest Exp TTM
$2,916,000,000
Analysts
28

Yahoo Snapshot (yfinance, live)

Total Revenue
$64,385,998,848
EBITDA
$30,762,999,808
Free Cash Flow
$16,870,250,496
Enterprise Value
$518,724,190,208
Total Cash
$6,568,999,936
Total Debt
$70,884,999,168
Shares Out
1,767,117,285
Trailing EPS
$3.55
Book Value
$-3.36
ROE
—
ROA
10.5%
Div Yield
2.69%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 61,160,000,000 20,091,000,000 4,226,000,000 133,960,000,000 137,188,000,000 -3,270,000,000 19,030,000,000
Dec 2024 56,334,000,000 11,894,000,000 4,278,000,000 135,161,000,000 131,797,000,000 3,325,000,000 18,806,000,000
Dec 2023 54,318,000,000 13,535,000,000 4,863,000,000 134,711,000,000 124,314,000,000 10,360,000,000 22,839,000,000
Dec 2022 58,054,000,000 18,814,000,000 11,836,000,000 138,805,000,000 121,518,000,000 17,254,000,000 24,943,000,000

TTM Snapshot

Revenues TTM
$56,542,000,000
NetIncome TTM
$8,574,000,000
OpCashFlow TTM
$0
Assets (Latest)
$133,960,000,000
Forward EPS
$16.28

Max Pain — expiry 2026-10-02 (volume-derived — Yahoo OI feed degraded)

max pain strike: $262.50 · spot: $264.34 · call volume: 1,194 · put volume: 710
Expected Move to 2026-10-02: ±$6.82 (2.58%) — implied range $257.52 – $271.16 · ATM straddle on $265.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MRK Merck & Co., Inc. $367.07B $148.78 —
JNJ JOHNSON & JOHNSON $653.61B $271.22 —
NVS NOVARTIS AG $276.48B $145.46 —
AZN ASTRAZENECA PLC $258.35B $166.58 —
LLY ELI LILLY & Co $1.06T $1183.46 —

News headlines (Yahoo Finance, 1h cache)

AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth
2026-09-27 20:28 · Yahoo
How to Build $7,250 a Month in Dividend Income Without Owning a Single Yield Trap
2026-09-26 16:15 · Yahoo
What Does AbbVie (ABBV) Need To Prove With Its Latest Pipeline Moves?
2026-09-26 16:12 · Yahoo
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-25 23:16 · Yahoo
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
2026-09-25 21:22 · Yahoo
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
2026-09-25 15:01 · Yahoo
RNAi drug specialist ADARx raises $446M IPO
2026-09-25 00:36 · Yahoo
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
2026-09-24 21:19 · Yahoo
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
2026-09-24 20:22 · Yahoo
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules
2026-09-24 19:39 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.